Press Relase
Multimmune GmbH and Boulder Diagnostics Inc announce the
development of an HSP70 lateral flow point of care test
Munich, Germany and Boulder Colorado, January 13th - Multimmune
GmbH and Boulder Diagnostics Inc. announce today the joint development
of an HSP70 lateral flow point of care test. Multimmune has discovered that
many tumor types display the heat shock protein 70 (Hsp70) on the cell
surface. Multimmune is exploiting this signal for directed immune therapy to
cure cancers. The HSP70 lateral flow point of care test is being developed to
test for elevated HSP70 levels in the blood of cancer patients and to evaluate
the correlation of this occurrence with the presence of the tumor specific
HSP70 cell surface marker. Boulder Diagnostics Inc. draws on its leading
competence in lateral flow assay development to develop the HSP70 point of
care test.
"The HSP70 point of care test will help us more rapidly to advance the
important concept of tumor therapy against HSP70 expressing cancers",
comments Claus Botzler, Managing Director of Multimmune GmbH.
"We are excited to apply our extensive lateral flow assay development
expertise to this novel and important diagnostic opportunity", states Dede
Willis, Chief Operating Officer of Boulder Diagnostics Inc.
About Multimmune:
Multimmune develops tumor therapies based on exploitation of tumorspecific
cell surface markers. Multimmune has advanced an ex vivo immune
recruitment therapy against HSP70 displaying colon and lung cancers
through clinical phase I and has demonstrated pre-clinical proof of concept
of an antibody therapeutic against HSP70 displaying tumors.
About Boulder Diagnostics:
Boulder Diagnostics is dedicated to the development of point of care lateral
flow diagnostic assays and is currently developing products to detect
elevated homocysteine levels and for the diagnosis of Lyme disease.
Contact
Download this press release as PDF
